Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSF1R | P07333 | 2/20 | 0.41 |
| ▸ | KIT | P10721 | 2/20 | 0.41 |
| ▸ | DYRK1A | Q13627 | 13/20 | 0.40 |
| ▸ | GSK3B | P49841 | 12/20 | 0.40 |
| ▸ | CLK2 | P49760 | 1/20 | 0.40 |
| ▸ | CLK3 | P49761 | 1/20 | 0.40 |
| ▸ | CTSV | O60911 | 1/20 | 0.40 |
| ▸ | CTSL | P07711 | 1/20 | 0.40 |
| ▸ | CTSB | P07858 | 1/20 | 0.40 |
| ▸ | CTSS | P25774 | 1/20 | 0.40 |
| ▸ | WNT1 | P04628 | 10/20 | 0.39 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.39 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.38 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.38 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.37 |
| ▸ | FYN | P06241 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25291841 | 1.00 | CSF1R (0.41) | CSF1RKITDYRK1AGSK3BCLK2 | |
| SCHEMBL25291840 | 1.00 | CSF1R (0.41) | CSF1RKITDYRK1AGSK3BCLK2 | |
| SCHEMBL25295934 | 0.92 | CTSV (0.41) | CSF1RKITDYRK1AGSK3BCLK2 | |
| SCHEMBL25295933 | 0.92 | CTSV (0.41) | CSF1RKITDYRK1AGSK3BCLK2 | |
| SCHEMBL25248340 | 0.89 | CTSV (0.39) | CSF1RKITDYRK1AGSK3BCLK2 | |
| SCHEMBL25301282 | 0.89 | CTSV (0.39) | CSF1RKITDYRK1AGSK3BCLK2 | |
| SCHEMBL25290177 | 0.89 | CTSV (0.39) | CSF1RKITDYRK1AGSK3BCLK2 | |
| SCHEMBL25814238 | 0.87 | KIFC1 (0.42) | CSF1RKITDYRK1AGSK3BCLK2 | |
| SCHEMBL25297055 | 0.82 | CTSV (0.39) | CSF1RKITDYRK1AGSK3BCLK2 | |
| SCHEMBL25292287 | 0.81 | CTSV (0.43) | CSF1RKITDYRK1AGSK3BCLK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250084074-A1 | SUBSTITUTED HETEROCYCLES AS HSET INHIBITORS | MERCK PATENT GMBH (DE) | 2025-03-13 | — | — | US | disclosed |
| EP-4463444-A1 | SUBSTITUTED HETEROCYCLES AS HSET INHIBITORS | Merck Patent GmbH (DE) | 2024-11-20 | — | — | EP | disclosed |
| WO-2023131690-A1 | SUBSTITUTED HETEROCYCLES AS HSET INHIBITORS | MERCK PATENT GMBH (DE) | 2023-07-13 | — | — | WO | disclosed |
| WO-2023131690-A1 | SUBSTITUTED HETEROCYCLES AS HSET INHIBITORS | MERCK PATENT GMBH (DE) | 2023-07-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250084074-A1 | SUBSTITUTED HETEROCYCLES AS HSET INHIBITORS | VHL, CDKN1A, CCNI | CSF1R 713/4885KIT 414/4885DYRK1A 3206/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.